Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ripertamab in Generalized Myasthenia Gravis
NCT07372807Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ripertamab in myasthenia gravis (MG). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
ripertamab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07372807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372807.